Monkeypox: Higher Risk for Immunocompromised, Vaccine Safe for HIV+
Health authorities warn that people with HIV-associated immunosuppression or other conditions may face a higher risk of severe monkey pox symptoms. Screening for STIs, including HIV, is advised for those evaluated for monkey pox. Immunosuppressive agents also pose an increased risk.
To manage monkey pox, health professionals should consider the use of tecovirimat or other therapeutics based on the individual's clinical situation. Postexposure prophylaxis and antiviral treatments are available for those exposed to or infected with the virus. Notably, people with monkey pox and HIV should commence antiretroviral therapy (ART) promptly to bolster immune function.
The JYNNEOS vaccine, manufactured by Bavarian Nordic, is deemed safe for immunocompromised individuals, including those with HIV or on immunosuppressive therapies. Vaccination is recommended to protect against monkey pox.
In summary, people with certain health conditions may be at greater risk of severe monkey pox symptoms. Screening, appropriate treatment, and vaccination are crucial for managing the virus. The JYNNEOS vaccine, produced by Bavarian Nordic, is safe for immunocompromised individuals.
